Annual Report 2009/2010 Geschäftsbericht 2009/2010 ... - biolitec AG

8 The Company Das Unternehmen
Investor Relations
The biolitec share
biolitec shares were introduced in November, 2000 to the stock market trade of the new market. The
share capital of the company amounts to EUR 10.515.750. In the course of the new segmentation of the
German stock market, biolitec has received the licensing to the Prime standard on the January 15th,
2003. Since that time, the biolitec share is dealt on the Prime-All-Share-Index, under the sectoral index
DAXsector All Pharma & Healthcare and the DAXsubsector All Medical Technologies. biolitec also issues
an annual declaration pursuant to the “German Corporate Governance Code” to guarantee its stockholders
an increased transparency. In November 2007, the group presented itself on a roadshow to institutional
investors. After this roadshow, biolitec could successfully conclude a capital increase for cash.
In June, 2008 the biolitec stock was recorded in the German Entrepreneurial Index (GEX®).
The stock year 2009/2010
During the fiscal year 2009/2010 the worldwide stock markets partially re-strengthened. After severe
problems at the stock exchanges in 2008 an economic consolidation on a low level could be seen at the
beginning of April 2009. The markets started trusting in the monetary measures taken by the government.
The prices of shares and bond issues increased continuously until October 2009. After October a
lateral movement of the market could be seen where only selective shares were able to increase in value.
In 2009, European shares increased by 27% (measured by the DJ Euro Stoxx) 1 . biolitec’s revenues did
not increase as expected, its profit is mainly due to cost-cutting measures.
The stock exchanges closed the first term with a deficit. High debts of countries like Portugal, Ireland,
Italy, Greek and Spain as well as the weak European and US economy affected the overall market situation
strongly. The markets were influenced by a weak Dollar and high oil prices.
biolitec’s shares were not able to distinguish themselves from the general tendency in the market. On
30 June 2010 the DAX closed at 5,966. Compared to last the end of 2009 the leading index increased by
only 0.14%. At the beginning of the fiscal year 2009/2010 the biolitec share opened with a value of EUR
3.97 on 1 July 2009. On 5 February 2010 the biolitec was at its annual low at EUR 3.45. During the rest of
the year its value varied between EUR 3.50 and 5.00. The shares’ price trend therefore closely followed
the Prime Pharma & Healthcare Index, which consists of 46 companies of the Prime Standard from the
sectors pharma, healthcare, biotechnology and medical-technology. For the complete second year of
2009 and from April 2010 the biolitec share developed better than the Prime Pharma & Healthcare Index.
The increased demand for biolitec shares beginning with February 2010 was proportional to an
increase of the trade flow and the share price. On 3 March 2010 the share reached its annual high in the
fiscal year 2009/2010 with EUR 5.00. On 30 June 2010 the share closed at EUR 3.65. At this point the
company had a market capitalization of approximately EUR 36.6 million.
On account of the low biolitec share value many investors re-invested in biolitec because from our point
of view it was underrated. In June 2009 an analyst of First Berlin took up the coverage of the biolitec
share. The advice of First Berlin analysts for biolitec share was “buying”.
1 Source: WesTLB Mellon Asset Management January 2010